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Background: Pseudomonas aeruginosa infections are a serious threat in intensive care units (ICUs). The aim of this
confirmatory, randomized, multicenter, placebo-controlled, double-blind, phase 2/3 study was to assess the efficacy,
immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in non-surgical ICU patients.
Methods: Eight hundred patients aged 18 to 80 years admitted to the ICU with expected need for mechanical
ventilation for ≥ 48 h were randomized 1:1 to either IC43 100 μg or saline placebo, given in two vaccinations 7 days
apart. The primary efficacy endpoint was all-cause mortality in patients 28 days after the first vaccination.
Immunogenicity and safety were also evaluated.
Findings: All-cause mortality rates at day 28 were 29.2% vs 27.7% in the IC43 and placebo groups, respectively
(P = .67). Overall survival (Kaplan-Meier survival estimates, P = .46) and proportion of patients with ≥ one confirmed
P. aeruginosa invasive infection or respiratory tract infection also did not differ significantly between both groups.
The geometric mean fold increase in OprF/I titers was 1.5 after the first vaccination, 20 at day 28, after the second
vaccination, and 2.9 at day 180. Significantly more patients in the placebo group (96.5%) had ≥ one adverse event
(AE) versus the IC43 100 μg group (93.1%) (P = .04). The most frequently reported severe AEs in the IC43 and
placebo groups were respiratory failure (6.9% vs 5.7%, respectively), septic shock (4.1% vs 6.5%), cardiac arrest (4.3%
vs 5.7%), multiorgan failure (4.6% vs 5.5%), and sepsis (4.6% vs 4.2%). No related serious AEs were reported in the
IC43 group.
Interpretation: The IC43 100 μg vaccine was well tolerated in this large population of medically ill, mechanically
ventilated patients. The vaccine achieved high immunogenicity but provided no clinical benefit over placebo in
terms of overall mortality.
Trial registration: https://clinicaltrials.gov (NCT01563263). Registration was sent to ClinicalTrials.gov on March 14,
2012, but posted by ClinicalTrials.gov on March 26, 2012. The first subject was included in the trial on March 22,
2012.
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Nosocomial infections are an increasing problem in in-
tensive care units (ICUs), with infection rates reportedly
two to five times higher than in the general inpatient
hospital population [1]. Elderly patients who are multi-
morbid, immunocompromised, and increasingly vulner-
able to antibiotic-resistant bacteria are particularly at
risk [2].
Pseudomonas aeruginosa is an invasive, gram-negative
bacterium that is known to cause a wide range of acute
and chronic infections [3]. P. aeruginosa rarely causes
infection in the healthy host, yet it is an efficient oppor-
tunistic pathogen that can cause serious infections in pa-
tients who have weakened immune systems, e.g.,
individuals who are immunocompromised, and patients
with malignancies or HIV infection [4]. P. aeruginosa is
one of the most common nosocomial pathogens and is a
major cause of morbidity and mortality for hospitalized
patients [5]. It is responsible for approximately 10% of
all hospital-acquired infections and has an estimated
mortality rate of up to 50% [5, 6]. It is common in ICU
patients with chronic disease and/or those who acquire
ventilator-associated pneumonia [7–10]. Despite the
availability of new classes of antibiotics, multidrug resist-
ance to P. aeruginosa has doubled over the past 30 years
[6–11]. Thus, new approaches are required to prevent
and cure P. aeruginosa infections. Vaccination strategies
that may confer long-lived adaptive immunity against
multidrug-resistant, gram-negative bacterial infections
have produced mixed results [12]. However, the investi-
gational vaccine IC43 appeared to be promising based
on the favorable safety and immunogenicity profile from
previous phase 1/2 studies [13, 14]. In the phase 2 study,
IC43 demonstrated a significant immunogenic effect in
ventilated ICU patients without safety concerns. In
addition, all-cause mortality was reduced versus placebo
(more pronounced in patients with infections), although
there were no significant differences in P. aeruginosa in-
fection rates [13].
In the current study, we sought to confirm the pre-
viously observed effects of IC43 100 μg on all-cause
mortality in a large, high-risk ICU population of med-
ically ill, intubated patients with the need for mech-
anical ventilation (MV).Methods
Study design
This was a confirmatory, randomized, multicenter,
placebo-controlled, double-blind phase 2/3 study to
assess the efficacy, immunogenicity, and safety of IC43
recombinant P. aeruginosa vaccine in ICU patients, with
a follow-up duration of 180 days after the first vaccin-
ation (NCT01563263).The study was conducted from 2012 to 2015 at 52 study
sites in six European countries (Austria, Belgium, Czech
Republic, Germany, Hungary, and Spain). The study was
approved by the responsible Ethics Committees and com-
pliant with the current International Conference on
Harmonization/Good Clinical Practice guidelines and in
accordance with the principles set forth in the Declaration
of Helsinki.
Patients
Medically ill patients admitted to an ICU with the ex-
pected need for MV for ≥ 48 h who were aged 18 to 80
years at screening were eligible for inclusion. Female pa-
tients were only included if they lacked childbearing po-
tential or had a negative pregnancy test. Written
informed consent was obtained in line with local regula-
tions. Exclusion criteria included a Sequential Organ
Failure Assessment (SOFA) score < 4 at day 0 (day of
screening), a previous organ transplant within the past
6 months, readmission to the ICU during the current
total hospital stay, admission to the ICU within 2 days
after surgery, admission to the ICU due to trauma, elect-
ive surgery until day 28 after the first vaccination, and
expected plasmapheresis or immunoadsorption. The use
of antibiotics was left to the discretion of the local physi-
cians treating the patients.
Interventions
Patients were randomized 1:1 to either receive IC43
100 μg (recombinant P. aeruginosa fusion protein con-
struct consisting of epitopes of OprF and OprI with an
N-terminal His 6 tag: Met-Ala-(His)6 – OprF 190–342
– OprI 21–83 protein [Valneva Austria GmbH, Vienna,
Austria]) [15] or placebo (phosphate-buffered saline so-
lution containing 0.9% NaCl). Each patient was planned
to receive a total of two intramuscular vaccinations (of
1 mL in the deltoid muscle of the same upper arm) 7
days apart, on days 0 and 7.
Study outcomes
The primary efficacy endpoint was all-cause mortality at
day 28 in patients receiving either IC43 100 μg or pla-
cebo. Secondary efficacy endpoints included all-cause
mortality at days 14, 56, and 90; all-cause mortality at
days 28, 56, and day 90 in patients surviving through day
14; all-cause mortality at days 14, 28, 56, and 90 in pa-
tients surviving through day 3; overall survival; and the
proportion of patients who had a P. aeruginosa infec-
tion/colonization within 28 and 56, 90, and 180 days
after first vaccination; further pre-planned statistical ana-
lyses provided infection rates between day 7 and day 14
and day 14 and day 90.
P. aeruginosa infections were diagnosed by the investi-
gator according to predefined diagnostic criteria [8, 16]
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mittee (DMC). For the collection of P. aeruginosa infec-
tion data, investigators obtained cultures from blood
samples, central venous catheter device samples, respira-
tory secretions, and urine as medically indicated, accord-
ing to the local standard of care. The fact that there was
no convincing signal concerning an effect of the vaccine
evaluated on P. aeruginosa infections in the phase 2 trial
in addition to the difficulties in interpreting over-
infection led to the decision not to screen per protocol
for infections in the phase 3 trial. Investigators docu-
mented P. aeruginosa infections (e.g., bacteremia, urin-
ary tract infection, pneumonia, tracheobronchitis) or
respiratory tract colonization. Organ function (SOFA
scores) was assessed at all visits performed at the ICU.
In addition, the length of ICU stay after the first vaccin-
ation and overall hospital stay were evaluated. Immuno-
genicity at days 7, 14, 28, 56, and 180 was determined by
measuring OprF/I-specific immunoglobulin G antibody
titer using an enzyme-linked immunosorbent assay.
Safety was evaluated up to 180 days after the first vaccin-
ation, including adverse events (AEs), serious AEs, and
laboratory parameters; systemic and local tolerability
were assessed during up to 7 days post vaccination.
Statistical analysis
A sample size of 800 patients (400 per group) was se-
lected to allow for the detection of a 10% difference in
mortality rates with a power ≥ 90% and an expected
mortality rate in the placebo group of 25 to 30% (two-
sided significance level of 5%; χ2 test without continuity
correction). Patients were randomized 1:1 into one of
the treatment groups using an ascending Investigational
Medicinal Product (IMP) kit number, where IMP kits
were prepacked according to the randomization plan
generated before the study starts with a block size of
four (two per group). The primary efficacy analysis com-
pared the difference in day 28 all-cause mortality (num-
ber of deaths until day 28/total number of observed
patients in treatment group) between the two treatment
groups in the intent-to-treat analysis population (ITT,
all randomized patients), using a Cochran-Mantel-
Haenszel test stratified for the country with the null hy-
pothesis of no difference between treatment groups and
a significance level of 5% (two-sided). In addition, logis-
tic regression was applied to assess the independent in-
fluence of treatment with covariates such as the country,
patient’s age, SOFA score, and the Acute Physiology and
Chronic Health Evaluation (APACHE) II score as covari-
ates. Survival endpoints were evaluated using Kaplan-
Meier curves and Cox regressions, with the factors treat-
ment group, country, patient’s age, and SOFA/APACHE
II score at day 0. SOFA scores after day 0 (visit 0) were
compared between treatment groups for each visit usinga van Elteren test stratified for the country. Geometric
mean titers and geometric mean titer ratios were esti-
mated by applying an analysis of variance including the
factors country and vaccination group after log10 trans-
formation. The geometric mean fold change of OprF/I
titers was also estimated. All patients who received at
least one vaccination and provided postvaccination
safety data were included in the safety analysis.
After enrollment of 50% of patients, i.e., after 400 pa-
tients, an interim analysis for futility was planned to
compare the day 28 mortality between the IC43 100 μg
group and placebo group and to allow discontinuation
of the study in case of insufficient vaccine effect. A con-
ditional power at the end of the trial of at least 60% was
used as the nonbinding futility criterion. All the study
staff including statisticians remained blinded for treat-
ment allocation during the interim analysis, which was
reviewed exclusively by the DMC and the study steering
committee.
SAS 9.3 TS1M2 (second maintenance release) was used.
Results
Between 2012 and 2015, a total of 812 patients were en-
rolled at 52 study centers (Fig. 1); 799 patients were ran-
domized to receive either IC43 100 μg (N = 393) or
placebo (N = 406). The ITT population included all ran-
domized patients. The number of patients who received
the second injection (IMP or PBS) was 344 (87.5%) in
the IC43 and 349 (86.0%) in the placebo group. Seven
hundred ninety-six patients who received at least one
IMP injection were included in the safety analysis.
The baseline characteristics of the study population are
presented in Table 1. There were no major differences in
terms of medical history between the two treatment
groups. The most common concomitant medications
were antibiotics for systemic use (98.2% [n = 782] and
antithrombotic agents (90.7% [n = 722]). Among the 629
patients (79.0%) treated with Pseudomonas-specific anti-
infective therapy, carbapenems were the most frequently
reported (41.3% [n = 329]). The number of days on anti-
biotic treatment was similar in the IC43 100 μg and pla-
cebo groups (mean 54.4 vs 52.0 days; median 16 days in
both groups). The use of systemic antibiotic treatments
before and after the second IMP injection was similar in
the IC43 and placebo groups when pooled across all coun-
tries (85.2% vs 83.6% and 63.4% vs 59.6%, respectively).
The number of patients receiving P. aeruginosa relevant
antibiotics at baseline or prior to inclusion was very high
(79%), being consistent with the literature [10, 17]. No
additional post hoc analysis of the group without P. aeru-
ginosa active antibiotics has been performed due to a
small sample size. The following antibiotics were consid-
ered relevant for P. aeruginosa: piperacillin, piperacillin/
tazobactam, ceftazidime, ceftirome, cefepime, group 1
Fig. 1 CONSORT diagram
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noglycosides, ciprofloxacin, levofloxacin, and aztreonam.
Primary efficacy endpoint
Overall, all-cause mortality rates were similar in the two
treatment arms; the proportion of patients who died
through day 28 was 29.2% (108/370 [95% confidence inter-
val (CI), 24.8–34.0]) in the IC43 100 μg group and 27.7%
(108/390 [95% CI, 23.5–32.3]) in the placebo groups
(P = .6740) (Fig. 2). However, there were substantial differ-
ences in all-cause mortality rates at day 28 between the dif-
ferent countries (Austria:29.5%, Belgium 33.8%, Hungary
35.0%, Germany 24.1%, Spain 18.5%, and Czech Republic
14.0%, for the total study population).
For the interim analysis (N = 394), the pre-specified,
nonbinding futility criterion was formally met; however,
the reduction in day 28 all-cause mortality between the
IC43 100 μg (28.3%) and placebo (32.8%) groups wasconsidered clinically meaningful by the DMC, and hence,
the study was continued.Secondary efficacy endpoints
In patients surviving through day 3, all-cause mortality
rates were similar in the IC43 and placebo groups (Fig. 2);
however, in patients who survived through day 14, all-
cause mortality rates were higher in the IC43 group vs the
placebo group, but the differences were not significant
(Fig. 2).
Overall survival (Kaplan-Meier survival estimates) did
not differ significantly between the groups (P = .4603)
(Fig. 3). Mortality rates were numerically slightly lower
in the IC43 group than in the placebo group on day 14
(17.1 vs 19.8%) and day 56 (37.6 vs 38.9%) and higher on
day 90 (44.4 vs 42.7%) and day 180 (60.6 vs 55.3%);
again, these differences were not significant.
Table 1 Baseline characteristics per treatment group (safety population)
IC43 100 μg (n = 393)No. (%) Placebo (n = 403)No. (%) Total (N = 796)No. (%)
Age, mean, years (min/max) 61.8 (18/86a) 62.0 (18/80) 61.9 (18/86)
Sex, no. (%)
Male 264 (67.2) 269 (66.7) 533 (67.0)
Female 129 (32.8) 134 (33.3) 263 (33.0)
BMI 28.9 28.5 28.7
Ethnicity, no. (%)
Caucasian 387 (98.5) 395 (98.0) 782 (98.2)
Asian 1 (0.3) 1 (0.2) 2 (0.3)
Black 4 (1.0) 5 (1.2) 9 (1.1)
Other 1 (0.3) 2 (0.5) 3 (0.4)
SOFA score, mean (±SD) 8.1 (± 2.9) 8.3 (± 2.8) 8.2 (± 2.8)
APACHE II score, mean (±SD) 18.7 (± 7.2) 19.8 (± 7.9) 19.2 (± 7.6)
Medical history (reported events > 15%), no. (%)
Hypertension 220 (56.0) 225 (55.8) 445 (55.9)
Pneumonia 160 (40.7) 162 (40.2) 322 (40.5)
Chronic obstructive pulmonary disease 92 (23.4) 105 (26.1) 197 (24.7)
Respiratory failure 78 (19.8) 91 (22.6) 169 (21.2)
Acute kidney injury 76 (19.3) 87 (21.6) 163 (20.5)
Atrial fibrillation 72 (18.3) 82 (20.3) 154 (19.3)
Obesity 71 (18.1) 69 (17.1) 140 (17.6)
Sepsis 70 (17.8) 52 (12.9) 122 (15.3)
Diabetes mellitus 68 (17.3) 66 (16.4) 134 (16.8)
Septic shock 63 (16.0) 72 (17.9) 135 (17.0)
Anemia 59 (15.0) 72 (17.9) 131 (16.5)
Hypotension 57 (14.5) 69 (17.1) 126 (15.8)
Prior medicationb
Antibacterials for systemic use 177 (45.0) 184 (45.7) 361 (45.4)
Antidiarrheals, intestinal anti-inflammatories 16 (4.1) 12 (3.0) 28 (3.5)
Antimycobacterials 7 (1.8) 8 (2.0) 15 (1.9)
Abbreviations: BMI body mass index, ICU intensive care unit, Q quarter, SOFA Sequential Organ Failure Assessment
aFive patients aged > 80 years were vaccinated; these constituted a major protocol deviation and were subsequently omitted from the per-protocol analysis
bPatients are counted only once per Anatomical Therapeutic Chemical level 2 (World Health Organization Drug Dictionary Q4_2015).
cIntent-to-treat population (IC43: n = 393; placebo: n = 406)
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nificant impact of treatment group on survival; however,
baseline SOFA score alone was negatively associated with
survival, independent of treatment group (P < .0001). Con-
comitant corticosteroid use also significantly affected sur-
vival, regardless of treatment group (P < .05) or treatment
group plus SOFA score (P < .05).
At all visits between days 0 and 180, mean SOFA scores
were similar in the IC43 100 μg (range, 2.0–8.1) and pla-
cebo (range, 3.4–8.2) groups (eTable 2 in the Supple-
ment). The mean length of ICU stay after the first IMP
injection was also similar between treatments (mean 22.3
vs 22.4 days; IQR, 19.0 vs 19.5 days), as was the length of
hospital stay (33.6 vs 34.5 days; IQR, 32 vs 30 days).The rates of patients with at least one DMC-confirmed
P. aeruginosa invasive infection or respiratory tract infec-
tion (e.g., pneumonia, tracheobronchitis) starting between
days 14 and 90 did not differ significantly between the
IC43 100 μg and placebo groups (eTable 1 in the Supple-
ment). In addition, no statistically significant differences
were seen for the other periods (e.g., day 0 to day 7). Over-
all, the rates of P. aeruginosa events were not significantly
different during the course of the study between the vac-
cination group and the placebo group respectively (bacter-
iemia 8 (2.0)% versus 11 (2.7%), P = 0.644; pneumonia 22
(5.6%) versus 32 (7.9%), P = 0.208; and urinary tract infec-
tion 7 (1.8%) versus 8 (2%) P = 1.000). P. aeruginosa re-
spiratory infections developed a median 10.8 and 11 days
Fig. 2 All-cause mortality (intent-to-treat population). aIC43 100 μg versus placebo
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respectively. Rates of patients with at least one DMC-
confirmed P aeruginosa respiratory tract colonization start-
ing between days 0 and 7, between days 0 and 28, and be-
tween day 0 and study’s end differed significantly between
the IC43 100 μg and placebo groups (5.1% vs 2.0%,
P = .0201; 8.4% vs 4.7%, P = .0438; 10.7% vs 6.4%, P = .0316,
respectively). No significant differences in DMC-confirmedFig. 3 Overall survival: Kaplan-Meier curves by treatment group (intent-to-t
reflect a number of subjects at risk. + Symbols denote censored patientsP. aeruginosa respiratory tract colonization were observed
between days 14 and 90 (P = .4591). Any P. aeruginosa re-
spiratory tract colonization was detected 48 (12.2%) of the
vaccination group and in 30 (7.4%) of the placebo group
(P = 0.024). This difference likely represents a play of
chance. Specific information on susceptibility to antibiotics
was not prospectively collected in this trial and is therefore
unfortunately not available to answer this question.reat population). Arrows depict vaccination time points. Numbers
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immunized with IC43 100 μg attaining peak OprF/I-
specific antibody titers > 1000 endotoxin units per
milliliter at day 28. The findings from the phase 2
study were confirmed with the geometric mean fold
increase in OprF/I titers ranging from 1.5 after the
first vaccination to a peak of 20 on day 28 after the
second vaccination and 2.9 at day 180. A detailed
summary of the immunogenicity findings is included
in Additional file 1.
A total of 5510 AEs were reported for 755 patients
(Table 2). The number of patients with at least one AE
was significantly higher in the placebo group (96.5%)
than in the IC43 100 μg group (93.1%) (P = .0365). The
most frequently reported AE (> 10% in any treatment
group) was diarrhea (109 patients; 13.7%) (Table 2).
The most frequently reported severe AEs in the IC43
100 ug and placebo groups were similar and included re-
spiratory failure (6.9% vs 5.7%), septic shock (4.1% vs
6.5%), cardiac arrest (4.3% vs 5.7%), multiorgan failure
(4.6% vs 5.5%), and sepsis (4.6% vs 4.2%). One patient of
the placebo group experienced a possibly related SAE (re-
spiratory failure); no related SAEs were reported in the
IC43 100 μg group.
Overall, the proportion of patients with reported local
reactions was low and comparable between the two
treatment groups (< 1% of patients in both groups). In
general, hematology and clinical chemistry parameters
were comparable between the two treatment groups at
all time points, with the exception of C-reactive protein.
Compared with the IC43 100 μg group, C-reactive pro-
tein levels were slightly raised at all time points in theTable 2 Incidence of adverse events per treatment arm
IC43 100 μg (n = 393)N
Patients with ≥ 1 AE 366 (93.1)
Most frequently reported AEs by preferred term (> 10%)a
Diarrhea 57 (14.5)
Pyrexia 43 (10.9)
Urinary tract infection 53 (13.5)
Decubitus ulcer 53 (13.5)
Pneumonia 47 (12.0)
Treatment-related AEs 27 (6.9)
Severe AEs 236 (60.1)
Treatment-related severe AEs 2 (0.5)
Serious AEs 227 (57.8)
Treatment-related serious AEs 0 (0.0)
Medically attended AEs 347 (88.3)
AEs occurring within 1 h after first vaccination 5 (1.3)
AEs occurring within 1 h after second vaccination 3 (0.8)
Abbreviation: AE adverse event
aPatients counted only once per preferred term (MedDRA 18.1). P values for pairwisplacebo group, but most notably at early termination
visit (mean 273.4 vs 67.6 mg/L, respectively).
Discussion
Despite the availability of new classes of antibiotics, mul-
tidrug resistance to P. aeruginosa has doubled over the
past 30 years and improvements in the management of
MDR PA pneumonia are a global challenge and unmet
clinical need [17, 18]. This is the first large randomized
trial to evaluate a vaccination strategy in complex med-
ically ill ICU patients requiring MV and aiming to de-
crease all-cause mortality at day 28. This study proved
the feasibility of vaccination and inducing specific im-
mune responses in a complex ICU patient cohort. While
the IC43 vaccine was demonstrated to be safe and im-
munogenic, no significant differences in all-cause mor-
tality or survival rates vs placebo were observed.
The study was undertaken to confirm the previously
observed promising effects of IC43 100 μg on all-cause
mortality and to evaluate the benefits and risks of using
vaccines in an ICU setting [13]. A previous phase 2
study in ICU patients requiring MV showed a signifi-
cantly lower mortality rate for the IC43 group (21.5%)
versus the placebo group (40%) at day 28 associated with
high immunogenicity in the IC 43 group. Other trials in-
cluding critically ill patients observed mortality rates of
about 25%, which are lower than the mortality observed
in the cohort of this phase 2 study [19]. In this context,
it needs to be stated that for sample size calculation of
the present IC43 trial, both the differences in mortality
rate and the predicted placebo mortality rate at the time
point of primary endpoint assessment (day 28) wereo. (%) Placebo (n = 403)No. (%) P value Total (N = 796)No. (%)
389 (96.5) .0365 755 (94.8)
52 (12.9) .5371 109 (13.7)
62 (15.4) .0747 105 (13.2)
52 (12.9) .8346 105 (13.2)
49 (12.2) .5971 102 (12.8)
50 (12.4) .9138 97 (12.2)
23 (5.7) .5599 50 (6.3)
235 (58.3) .6653 471 (59.2)
2 (0.5) 1.0000 4 (0.5)
232 (57.6) 1.0000 459 (57.7)
1 (0.2) 1.0000 1 (0.1)
356 (88.3) 1.0000 703 (88.3)
8 (2.0) .5783 13 (1.6)
3 (0.7) 1.0000 6 (0.8)
e comparisons: Fisher’s exact test
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phase 2 study. The missing correlation between the ob-
served mortality benefit and confirmed P. aeruginosa in-
fections in the initial phase 2 trial required a phase 3
trial. In retrospect, probably another phase 2b trial
performed in a more selected population at risk (or
even colonized with P. aeruginosa) would have been
more appropriate. In addition, choosing P. aerugi-
nosa-related event as a broader primary endpoint may
have been an option.
In the current study, vaccination with IC43 resulted in
strong and consistent humoral responses; the absence of
clinical efficacy of IC43 vaccination was therefore prob-
ably not due to failure to elicit an antibody response.
However, antibody responses were limited at day 7 (i.e.,
16.6% SCR), before the second dose was administered. It
is possible that the time course of antibody development,
even at 2 weeks, is insufficient to influence clinical out-
come in acute, critically ill patients. Furthermore, as
stated before, the rates of patients with at least one
DMC-confirmed P. aeruginosa infection did not differ
significantly between the IC43 100 μg and the placebo
group. Instead, there was even a statistically significantly
higher rate of respiratory tract colonization in the vacci-
nated group compared to the placebo group. In the ab-
sence of any effect on P. aeruginosa infections, we
assume this to be a chance observation, not unlikely
given the number of statistical tests. The hypothesis that
antibody titers elicited with the IC43 100 μg vaccine,
particularly after the second vaccination, could result in
a reduction of P. aeruginosa infections could not be con-
firmed. Unlike in the previous phase 2 study, in the
current trial, P. aeruginosa was not actively screened for
per protocol, and this was left to the discretion of the
treating physician.
An additional difference compared to the IC43 phase
2 study was the restriction of the study population to
medically ill ICU patients, in which the greatest clinical
benefit could be expected. Due to the high-risk patient
population studied, the mortality rate had reached
roughly a fifth (17.1 vs 19.8%) of the included patients
by day 14, limiting the number of potential endpoints
occurring after the specific antibody titers peaked on day
28. In this context, it needs to be stated that the ob-
served mortality rate up to the time point of primary
endpoint assessment (day 28) was well within the ex-
pected mortality rate of 25 to 30%.
The high rate of systemic antibiotics already initiated
before study inclusion (79% of patients received agents
effective against Pseudomonas) potentially reduces the
effect of a vaccine. The fact that most patients were re-
ceiving antibiotics prior to vaccine dosing was expected
because prior antibiotic exposure is consistently identi-
fied as a risk factor for nosocomial P. aeruginosapneumonia [20]. Moreover, overall, approximately 98%
received concomitant antibiotics during the trial, and it
will be therefore not possible to explore potential inter-
actions between vaccination and antibiotic exposure on
P. aeruginosa isolates.
The rates of Pseudomonas colonization, which occur
early during an ICU stay, are also a factor mitigating
against vaccine effect, particularly since they were signifi-
cantly higher at baseline and throughout the study in the
IC43 100 ug group. However, the observed rates of
Pseudomonas infection and colonization were not greatly
different from those closely monitored in the phase 2
study. In addition, a certain level of uncertainty remains
with respect to truly distinguishing P. aeruginosa infection
from P. aeruginosa airway colonization based on respira-
tory clinical specimens, even with the use of predefined
diagnostic criteria.
A proof of efficacy for the IC43 antigen against P. aer-
uginosa has not firmly been established in humans des-
pite several promising earlier small-scale studies [5, 15].
It is possible that the induced antibodies were not pro-
tective. Despite a number of possible targets, the high
variability between Pseudomonas species and the com-
plexity of its infection process and interaction with the
host’s immune response has made it difficult to develop
an effective vaccine difficult [9].
In a planned interim analysis conducted after 394 pa-
tients were enrolled, results demonstrated a 4.5% abso-
lute mortality reduction in the IC43 100 ug group
compared with the placebo group. Though the pre-
specified nonbinding futility criterion was formally met,
the DMC recommended continuation of the trial and the
sponsor endorsed the decision. The attributable mortality
of P. aeruginosa infection in mechanically ventilated pa-
tients is dependent on the severity of illness, susceptibility
pattern, and appropriate antibiotic prescription, being esti-
mated to be around 13% [21, 22]. Thus, a 10% reduction
in mortality would have been very optimistic, a factor that
had been taken into account for the decision to continue.
In the second part of the study after the interim analysis,
the trend was in fact overturned with higher overall mor-
tality at day 28 in the active treatment group, resulting in
an increase of 1.5% when compared to placebo at the final
analysis. The absolute mortality rates observed in the in-
terim analysis were well within the 95% CI limits of the
mortality rates at the final analysis and were, therefore,
not improbable. This is a common problem of phase 3
ICU trials where encouraging earlier analyses were re-
duced or abolished after larger trials in these complex
study populations [23].
One of the limitations of this trial is that P. aeruginosa
events were not screened for by protocol, but this was
left to the discretion of the treating physician. It was per-
formed according to local standards of care. Therefore,
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events has been underestimated. The rationale for not
providing antibiotic policies was chosen in order to show
the effect of the vaccine on top of general practice anti-
biotic background therapy in this multinational trial and
due to the heterogeneity of susceptibilities and mecha-
nisms of resistance of the pathogen [24] which would re-
quire a personalized approach depending of different
ICUs’ (52 sites) predominant mechanisms of resistance.
The inclusion of patients from different European
countries may have introduced some variability in the
current study as there is great variation in the standards
of care for patients requiring long-term MV across Eur-
ope [25]. Furthermore, by including centers from differ-
ent countries and additional centers than were included
in the phase 2 study [13], some of which contributed
only few subjects for analysis, it is possible that a change
in enrollment of the patient type may have enhanced the
variability of the ICU population pool. Heterogeneity of
ICU populations is a recognized factor in interventional
trials, and while the eligibility criteria were not altered
during the current study, possible selection bias through
different regional referral patterns may have led to a
broader patient selection or earlier/later intervention. In
line with these interpretations, the country of residence
was shown to be a significant factor for survival/mortal-
ity in several regression models. Choosing a clinical and
statistically significant improvement in all-cause mortal-
ity as the primary endpoint, which is of course very diffi-
cult to reach in clinical trials performed in intensive care
patients, as well as the lack of an enrichment strategy in
order to include a more selected ICU patient population
at higher risk for P. aeruginosa may be considered, retro-
spectively, very challenging for the design of a study
protocol.
Interventions to prevent nosocomial infection using a
vaccine at the time point of ICU admission may come
too late, and potentially, vaccination before admission
would allow more time to show an effect. A large, ran-
domized trial investigating an S. aureus vaccine adminis-
tered weeks before elective cardiothoracic surgery failed
to reach its primary endpoint [26]. It remains unclear
whether vaccine candidates using other S. aureus anti-
gens could be efficacious prophylactically; similarly,
some subsets of patients exposed at high risk of P. aeru-
ginosa, such as those requiring prolonged MV for elect-
ive surgery, could benefit from preoperative vaccination
with other P. aeruginosa vaccine candidates. As stated
above, the primary endpoint of the present study was
chosen based on the results of the preceding phase 2
study. Clearly, achieving mortality reduction in a broad
ICU population would have been interesting, as an im-
pact on mortality is very difficult to demonstrate in
critically ill patients. The main reason for continuing thetrial after the formal, nonbinding futility criterion was met
was that the observed absolute mortality difference of
4.5% represented a clinically important signal bearing the
many negative previously performed ICU trials in mind.
However, the trial confirmed good immunogenicity
and an acceptable safety profile. Despite evident im-
munogenicity between days 7 and 14, P. aeruginosa in-
fection occurred prior to the development of IgG
immune response. This suggests that the effectivity of
pre-emptive administration before elective surgery in
high-risk patients needs to be explored. The enhance-
ment of innate and adaptive immunity remains a
promising approach to vanquish emerging MDR and
XDR P. aeruginosa [27].
Conclusion
The present study evaluated the concept of vaccination as
a strategy to reduce mortality and to prevent a potentially
lethal infection with P. aeruginosa in ventilated non-
surgical ICU patients. IC43 100 μg vaccination was both
immunogenic and well tolerated; however, there was no
clinical benefit of IC43 compared to placebo treatment.
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